BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20180101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190116
DTEND;VALUE=DATE:20190118
DTSTAMP:20260514T232817
CREATED:20180906T102552Z
LAST-MODIFIED:20180906T102552Z
UID:17513-1547596800-1547769599@www.pharmajournalist.com
SUMMARY:Pre-Filled Syringes & Injectable Drug Devices Europe
DESCRIPTION:SMi is proud to present their 11th annual European conference and exhibition\, within the Pre-Filled Syringes series: Pre-Filled Syringes & Injectable Drug Devices Europe. The event will take place on the 16th-17th of January 2019\, in London. \n \nThe conference will offer a deep insight into key areas within the field\, such as: new technologies and overcoming their hurdles to implementation; connectivity for devices; updates on drug development and the impact on device developments and new regulatory guidelines. Our line-up of expert speakers will enable delegates to learn from market leaders on best practices to overcome common industry hurdles. \nJoin us in January 2019 to network\, benchmark and learn about developments at the forefront of the Pre-Filled Syringes and Injectable Drug Devices industry. \nChairs for 2019: \n\nJames Mellman\, Device Manager\, Novartis\nAnil Busimi\, Strategy and Innovation Global Product Manager\, SCHOTT \n\nFeatured Speakers: \n\nAnil Busimi\, Strategy and Innovation Global Product Manager\, SCHOTT \nCedric Gysel\, Staff Device Engineer\, Janssen\nDavide Mercadante\, Sr Associate Quality Drug Devices\, Biogen\nElise Legendre\, Head of Late stage PFS Development\, Sanofi\nJames Mellman\, Device Manager\, Novartis\nJoan Malmstrom\, Principal Scientist\, Novo Nordisk \nJustin Wright\, Global Head of Innovation\, Novartis\nMaggie Reiff\, Associate Device Engineer\, Pfizer\nMathieu Rigollet\, Senior PFS Engineer\, Roche\nMichael Becker\, Design Engineer\, Boehringer Ingelheim \nReinhard Scheller\, Commercial ManagerCyclo Olefin Polymers – COP Europe\, Zeon Europe GmbH\nShota Arakawa\, Researcher\, Mitsubishi Gas Chemical Company\nStephen Barat\, Head of Pre-Clinical and Early Clinical Development\, SCYNEXIS \nSteve Chamberlain\, Device Engineering Manager\, GSK\nSuraj Ramachandran\, Director\, Merck\nVikas Jaitely\, Senior Manager Pharmaceutical Sciences & CMC Regulatory Intelligence\, Merck\n\nKey Highlights this January: \n\nEngage and interact with like-minded individuals through 5+ hours of dedicated networking time\, within the conference programme\nGain insight from fellow field experts through our interactive programme structure and our fantastic delegation with representation from all aspects of the industry\, as well as cross-industry thought leaders and decision makers\nDiscover new technologies being developed to circumvent common industry hurdles and discuss ways in which to overcome the barriers of implementation\nHear case studies about the streamlining of injectable device development – from development to market\nInteract with regulatory bodies in order to glean insight into the most recent revisions to regulation and the best ways to integrate them into business practices\nLearn about current drug development programmes which will have an imminent impact on the PFS and Injectable devices sector and discuss the influence which drug development has on device development\nDiscuss patient centricity and the impact of human factors on design processes\n\nView the full agenda online: www.pre-filled-syringes.com/PJ \nEARLY-BIRD RATES: \n\nBOOK BY 28TH SEPTEMBER AND SAVE £400\nBOOK BY 31ST OCTOBER AND SAVE £200\nBOOK BY 30TH NOVEMBER AND SAVE £100\n\nSponsored by: Mitsubishi Gas Chemical\, HarroHoefliger\, PHC Corporation\, Zwick Testing Machines\, Nemera\, Schott\, Zeon\, Fruh ALPHABETICAL ORDER
URL:https://www.pharmajournalist.com/event/pre-filled-syringes-europe/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:hsidhu@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190121
DTEND;VALUE=DATE:20190123
DTSTAMP:20260514T232817
CREATED:20171019T063411Z
LAST-MODIFIED:20180831T072922Z
UID:3491-1548028800-1548201599@www.pharmajournalist.com
SUMMARY:Social Media in the Pharmaceutical Industry
DESCRIPTION:SMi Group are delighted to present the return of their 11th annual Social Media in the Pharmaceutical Industry conference to London on the 21st– 23rd January 2019. \n \nSocial media is the perfect channel for pharmaceutical companies to educate\, market\, listen and connect with customers\, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients. \nJoin SMi’s 11th annual Social Media in the Pharmaceutical Industry conference to learn the best way your company can benefit froma robust social media strategy. Hear from industry experts on how to leverage social media platforms by keeping the patient at the forefront and exploring the latest advances in digital application such as Artificial Intelligence\, challenges and techniques in the field of ‘social pharma’. \nHow Will You Benefit? \nNetwork and learn from leading professionals such as: \n\n[CHAIR] – Jason Browning\, Global Head of Digital Communications & Social Media\, Novartis\n[CHAIR] – Emma Sutcliffe\, Director Patient Engagement and Innovation\, NexGen Healthcare Communications\nRoeland Van der Heiden\, Digital Director\, AstraZeneca\nLin Lei\, Associate Director Digital Customer Engagement\, Teva\nJoao Bocas\, CEO\, DigitalSalutem\nPaul Tunnah\, CEO\, PharmaPhorumMedia\nJacob D Flindt\, Founder\, pro\nAlan Shaw\, Director\, Strategic Planet; Senior Lecturer: Digital Marketing\, Northumbria University\nDennis Fink\, Campaign Manager and Social Media Channel Expert\, Qiagen\nStefania Alvino\, Multichannel Manager\, Daiichi Sankyo Co.\, Ltd.\n\n2019 Featured Highlights: \n\nExplore a result driven\, value focused social media strategy in the pharmaceutical industry\nGain insight into procedures and practices required prior to the implementation of social listening\nDiscuss how to personalise the content relationships with AI\nUnderstand the optimisation of disease awareness through social media channels\nLearn how to use social networks and digital communication to engage HCPs\nGDPR regulations and limitations to product advertisement (with case studies)\nPharmacovigilance in social media – specifically in adverse events reporting\n\nCheck out the brochure online: www.social-media-pharma.com/pj \nEarly-Bird Rates \n\nREGISTER BY 29TH SEPTEMBER AND SAVE £400\nREGISTER BY 31ST OCTOBER AND SAVE £200\nREGISTER BY 30TH NOVEMBER AND SAVE £100
URL:https://www.pharmajournalist.com/event/social-media-pharmaceutical-industry/
LOCATION:Holiday Inn London – Kensington Forum
ORGANIZER;CN="SMi Group Ltd":MAILTO:psolanki@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190121
DTEND;VALUE=DATE:20190123
DTSTAMP:20260514T232817
CREATED:20180906T115651Z
LAST-MODIFIED:20180906T115737Z
UID:17521-1548028800-1548201599@www.pharmajournalist.com
SUMMARY:SMi’s 8th Annual Pharmaceutical Microbiology
DESCRIPTION:SMi’s 8th Annual Pharmaceutical Microbiology: Addressing the key challenges\, trends and strategies in contamination control  \nConference: 21st & 22nd January 2019\nWorkshop: 23rd January 2019\nLocation: Copthorne Tara Hotel\, London\, UK\nWebsite: http://www.pharma-microbiology.com/PharmaJournWL \nSPONSORED BY: GOLD SPONSOR: DuPont; SPONSORS: Mettler Toledo\, Biomerieux and Copan Group  \nCHAIRED BY:\nJames Drinkwater\, Chairman\, Pharmaceutical & Healthcare Sciences Society\nOlivier Chancel\, Sterility and Aseptic Process Assurance\, Expert\, Boehringer Ingelheim \n \nThe pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods\, revisions being made to regulations in the industry\, enhanced knowledge of the human microbiome\, and novel testing methods\, this industry is ever expanding. In fact\, the value of the rapid microbiology testing market is expected to reach USD 6.2 Billion by 2022\, expanding at a CAGR of 7.3% from 2016 to 2022. This is the 8th year of a conference which is continually run by SMi and which has been very successful over the past few years. \nDeveloping on last years’ success\, Pharmaceutical Microbiology UK 2019 will bring together industry experts to discuss and analyse the latest advancement and challenges within pharmaceutical microbiology. Discover how you can keep up with regulatory changes and maintain the utmost efficiency during production and testing.  \nEvent Hashtag: #PharmaMicro \nAt the 8th Annual Pharmaceutical Microbiology Conference\, you will gain insight into: \n\nChallenges in development of a contamination control strategy for different product types\nA series of learning experiences within contamination from Boehringer Ingelheim\nThe use of vaporized hydrogen peroxide bio-decontamination technology in microbiology contamination control\nCase studies in deinococcus and fungal and bacterial spores in cleanrooms\nInfluence of temperature of incubation on results of microbiological environmental monitoring\nRisk mitigation strategies for animal-derived raw materials\n\nFEATURED SPEAKERS INCLUDE: \n\nAlexander Stoll\, VP Competence Center Microbiology & Aseptic Technique Quality Management\, Fresenius Kabi\nDi Morris\, Senior Manager\, Team Leader\, Vaccines Quality Audit\, GSK\nMarine Marius\, Scientist\, Analytical Research & Development Europe\, Sanofi Pasteur\nPhilippe Dutot\, Sterility Assurance Specialist\, Novo Nordisk\nRenate Rosengarten\, Professor and Chair of Bacteriology and Hygiene\, University of Veterinary Medicine Vienna\nThierry Bonnevay\, Microbiology Platform Head\, Analytical Research and Development\, Sanofi Pasteur\nTim Eaton\, Sterile Manufacturing Specialist\, AstraZeneca \n\nKEY TOPICS FOR 2018 INCLUDE: \n\nRapid Microbial Methods\nRevision of Annex 1 and impact on pharmaceutical microbiology\nContamination control strategies and case studies\nMycoplasma detection\, prevention and control\nFuture of endotoxin testing in pharmaceutical industries\nStrengths and weaknesses of vaporized Hydrogen peroxide as a bio-contamination control agent\nMold contamination control\nInfluence of temperature of incubation on results of microbiological environmental monitoring\n\nWHO SHOULD ATTEND \nSenior Microbiologist\, Lead Scientist\, Laboratory Manager\, QA Specialist Drug Substance External Manufacturer\, Business Development Manager – Testing\, Pharmaceutical Microbiology Consultant\, Higher Pharmacopoeia Scientist\, Analytical Standards Specialist \nEARLY BIRD-RATES \n\nBOOK BY 28TH SEPTEMBER AND SAVE £400\nBOOK BY 31ST OCTOBER AND SAVE £200\nBOOK BY 30TH NOVEMBER AND SAVE £100\n\nTo learn more about this event\, and to register online\, visit http://www.pharma-microbiology.com/PharmaJournWL
URL:https://www.pharmajournalist.com/event/8th-annual-pharmaceutical-microbiology/
LOCATION:Copthorne Tara Hotel\, Scarsdale Place\, Kensington\, London\, W8 5SY\, United Kingdom
ORGANIZER;CN="SMi Group Ltd":MAILTO:ssapal@smi-online.co.uk
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190128
DTEND;VALUE=DATE:20190131
DTSTAMP:20260514T232817
CREATED:20181116T143343Z
LAST-MODIFIED:20181116T154350Z
UID:18443-1548633600-1548892799@www.pharmajournalist.com
SUMMARY:3rd Microbiome Movement – Drug Development Europe
DESCRIPTION:Recent breakthroughs in DNA sequencing\, metagenomic analysis and computational techniques have given scientists new insight into the structure and function of the human microbiota\, an interconnected community of symbiotic\, commensal and pathogenic microorganisms. As valuable clinical data solidifies the importance of the human microbiome on human health and disease\, recent efforts have sought to harness this research to create microbiome-based therapeutics. \n \nSituated at the heart of therapeutic R&D\, the Microbiome Movement – Drug Development Summit kick starts 2019\, once again to help large pharma\, biotech and academic institutions accelerate the discovery\, clinical development of safe\, effective and commercially scalable microbiome therapeutics across a broad range of disease indications. \nSet to tackle the greatest scientific\, regulatory\, clinical\, manufacturing and commercialisation challenges across the entire drug development value chain\, this meeting will showcase leading industry case studies focused on enhancing the application of novel technologies to standardise results\, accelerate target discovery and optimise the translation of microbiome research into safe and effective therapeutic products. \nView the complete programme here.
URL:https://www.pharmajournalist.com/event/3rd-microbiome-movement-drug-development-europe/
LOCATION:Novotel Paris Est\, Paris\, France
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20190130
DTEND;VALUE=DATE:20190201
DTSTAMP:20260514T232818
CREATED:20181031T153442Z
LAST-MODIFIED:20181031T154321Z
UID:18198-1548806400-1548979199@www.pharmajournalist.com
SUMMARY:3rd Annual CAR-T Congress EU
DESCRIPTION:CAR-T cell therapy has shown unparalleled success in haematological malignancies\, paving the way for the field of immuno-oncology. In 2017 two therapies achieved FDA approval in the USA\, and following recent approval by the EMA\, it is a landmark time for the industry. \n \nDespite the huge successes there are still a number of hurdles to overcome before CAR-T can be effective in mainstream oncology beyond haematological malignancies. The European CAR-T Congress’ mission is to address the opportunities and challenges that presently face the CAR-T field\, to maximise the potential of this ground-breaking therapy. \nHear first-hand the story behind the successes of Novartis & Kite on their roads to approval. Discover how to improve manufacturing with automation to lower cost and increase the scope and reach of the therapies from innovators such as Torque Therapeutics. Explore the viability of allogeneic CAR-T with Cellectis\, Celyad and Servier on their approaches to off-the-shelf products. Atillio Bondanza also shares strategies to improve safety with a better understanding of the underlying mechanisms of toxicity. \n20+ industry leaders will be offering insight on: \n\nSolid tumour targeting: overcoming the tumour microenvironment\nMulti-specific & dual targeting CARs\nProcess development\, scalability & automation\nAllogeneic vs Autologous: the potential of off-the-shelf therapies\nPatient access\, implementation & regulatory challenges\nAdvances in gene engineering\nSafety and toxicity\n\nThere is also a dedicated poster session\, whereby attendees can showcase their latest research to the CAR-T community\, deadline for submissions 14th December 2018. \nSave up to £300 by booking on the early bird rate before Friday 30th November 2018. 2019 is going to be a big year for CAR-T in Europe\, don’t be the one to miss out on the latest developments. \nTo learn more about this event\, and to register online\, visit www.car-tcongresseu.com
URL:https://www.pharmajournalist.com/event/3rd-annual-car-t-congress-eu/
LOCATION:Millennium Gloucester Hotel\, 4-18 Harrington Gardens\, Kensington\, London\, SW7 4LH\, United Kingdom
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR